Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.
Press releases published on May 12, 2025
Advent Technologies Announces Dr. Ryan Pavlicek as General Manger of Livermore Facility
GlobeNewswire
·
May 12, 2025
LIVERMORE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ: ADN) ("Advent "or the "Company"), an innovation-driven leader in the fuel cell and hydrogen technology sector, is pleased to announce that Dr. Ryan Pavlicek has …
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
GlobeNewswire
·
May 12, 2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to scale business and operations WALTHAM, …
Collegium Announces $25 Million Accelerated Share Repurchase Program
GlobeNewswire
·
May 12, 2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it …
ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
GlobeNewswire
·
May 12, 2025
Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human Parkinson’s disease ABLi’s proprietary Re-engineering Approach …
CPS Technologies to Participate in Sidoti Microcap Virtual Conference
GlobeNewswire
·
May 12, 2025
NORTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that, as it did last year, the Company will participate in the Sidoti Microcap Virtual Conference on May 21 and 22, 2025. A …
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire
·
May 12, 2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In- …
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 12, 2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB …
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
GlobeNewswire
·
May 12, 2025
Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of …
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 12, 2025
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway …
Harvard Bioscience Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line …
Sionna Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination …
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
GlobeNewswire
·
May 12, 2025
MILAN, May 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the presentation of two …
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 …
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
GlobeNewswire
·
May 12, 2025
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease …